US HEVA Rare Asset/Indication Lead

Sanofi•Morristown, NJ

13d•Remote

About The Position

Sanofi is an R&D-driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is committed to advancing breakthroughs in cancer care and rare diseases, expanding scientific understanding and improving outcomes for patients facing these serious, often life-threatening conditions. Through a focused and growing portfolio of innovative therapies, Sanofi aims to address critical gaps in care and deliver meaningful, potentially transformative treatment options for underserved patient communities. We are one bold HEOR team leveraging innovative HEOR to transform patient care and access. As HEOR experts, we lead the generation and dissemination of robust, business-relevant evidence to demonstrate value and drive access to medicines. The HEVA organization is driven by five core values that define how we work and deliver impact. We operate as One Team, partnering without boundaries while pursuing a Bold Purpose through ambitious, measurable goals. Grounded in Scientific Excellence with Relevance and deep technical expertise, we embrace Innovation in Action to transform how we research and deliver Impact for People, creating meaningful outcomes for patients, the healthcare ecosystem, and our colleagues who make it all possible. This role is accountable for leading US HEOR strategy and execution for the Rare Hemophilia portfolio — including ALTUVIIIO, QFITLIA, Eloctat & Alprolix, and Cablivi (aTTP) — serving as the primary US HEVA point of contact for the portfolio and partnering cross-functionally to drive the generation, translation, and dissemination of high-quality, decision-relevant evidence to support access in the United States.

Requirements

Advanced degree (PhD, MD, MSc, MPH, or PharmD) in health economics, epidemiology, public health, economics, pharmacy, or a related field
3-5 years of experience in health economics, outcomes research, or a related field
Demonstrated experience in applying various HEOR methods and understanding the principles of evidence-based medicine and clinical research; strong publication record is a strong plus
Knowledge of global HTA processes and guidelines
Understanding of US healthcare system and payer dynamics, with ability to translate evidence into strategic insights
Experience supporting market access and reimbursement through HEVA evidence (e.g., value tools, evidence summaries, AMCP dossier contributions)
Working knowledge of US evidence dissemination (HCEI/PIE, reactive/proactive, CFL)
Experienced in statistical analysis methods relevant to HEOR, including ability to critically evaluate and apply quantitative evidence to support value demonstration and payer engagement
Foundational knowledge of AI and digital tools relevant to health economics, including familiarity with data analytics platforms and digital research tools; demonstrated willingness to develop proficiency with new AI-enabled solutions to support HEOR research and evidence generation

Nice To Haves

Experience in rare disease therapeutic areas preferred, including understanding of disease areas, treatment paradigms, and market dynamics
US launch experience preferred; understanding of US payer evidence requirements and value demonstration in a competitive market
Experience in rare disease therapeutic areas preferred, including understanding of disease areas, treatment paradigms, and market dynamics

Responsibilities

Develop and implement US payer-specific HEVA strategy in close collaboration with cross-functional team members to lead/implement VEST team structure for rare hemophilia portfolio.
Drive measurable business impact through execution of HEVA tactics that directly support commercial objectives and market access goals compliantly and efficiently.
Execute comprehensive US HEVA tactics for the Rare Hemophilia portfolio, contributing to strategic planning and ensuring alignment with broader portfolio objectives
Partner with commercial teams to translate HEVA insights into actionable business strategies
Partner with access and medical team members to generate and disseminate actionable high-impact evidence
Develop business-relevant US research agendas through cross-functional input and alignment, ensuring evidence priorities are reflected in broader Sanofi planning documents
Build and maintain strong relationships with cross-functional teams to ensure pricing and access decisions are aligned with the demonstrable value of the Rare Hemophilia portfolio
Align closely with the Global HEVA team to ensure US insights inform global strategies and coordinate evidence generation, modeling, and evidence synthesis activities
Communicate complex health economics concepts and strategic recommendations to cross-functional stakeholders with clarity and impact
Influence key business decisions through data-driven insights and strategic HEVA recommendations
Ensure clinical development plans for Rare Hemophilia indications are designed to deliver true differentiation aligned to Sanofi's best-in-class or first-in-class ambition
Oversee the design, execution, and publication of high-quality health economics and outcomes research studies — including economic modeling, database analysis, observational research, systematic literature review, evidence synthesis, and AMCP dossier development — for the Rare Hemophilia portfolio
Contribute to the development of comprehensive real-world evidence strategies that support product lifecycle management
Ensure scientific rigor and regulatory compliance across all HEVA tactics
Support the development of global launch strategies and provide strategic HEVA input into Integrated Evidence Generation Plans (IEGPs) for Rare Hemophilia indications to ensure alignment across clinical, real-world evidence, and value demonstration objectives
Execute all HEVA tactics at the highest level of quality to compliantly further HEOR evidence dissemination, application, and proactive and/or promotional use with US stakeholders (HCEI, PIE)
Apply data-driven decision-making frameworks to prioritize evidence gaps and guide research investment decisions for the Rare Hemophilia portfolio, ensuring alignment between identified data gaps and strategic evidence generation priorities.
Represent Sanofi at major scientific conferences and industry forums, leading abstract development and presentation delivery for the Rare Hemophilia portfolio
Collaborate with external research partners and key opinion leaders to advance HEVA strategy and tactical plans in Rare Disease
Manage the US HEVA budget for the Rare Hemophilia portfolio, overseeing vendor contracts, research investments, and resource allocation to ensure delivery of evidence generation priorities within budget constraints
Work with the team lead to engage with external evidence bodies (ICER, PDAB, IRA) and apply knowledge of their requirements to shape evidence generation and value demonstration strategies for Rare Disease